Industry

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Vision Monday5d ago1 min read

MENLO PARK, Calif.—Eyecare tech company Sight Sciences, Inc. (Nasdaq: SGHT) announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the indications for use for its TearCare System, allowing it to be used for improving meibomian gland function in adult patients with evaporative dry eye disease resulting from meibomian gland dysfunction (MGD). As a result of this expanded indication, TearCare is now the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease, the company said.

Read full article on Vision Monday

AI Summary

Quick Take

The FDA has expanded the indications for Sight Sciences’ TearCare System, making it the first and only device specifically indicated to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This regulatory update shifts the system's labeling from a general heat application to a specific therapeutic outcome for gland performance.

Why It Matters

While thermal treatments for MGD are common, regulatory indications have historically focused on the delivery of heat rather than the physiological restoration of gland function. This expanded indication provides clinicians with a cleared, functional claim to use when discussing the therapeutic value of the procedure with patients. In a competitive dry eye market, this distinction may influence clinical protocols and could eventually impact how payers view the medical necessity of the procedure.

Key Details

The FDA update for the TearCare System is effective as of August 18, 2026.
The system is now specifically indicated for improving meibomian gland function in adult patients.
The indication targets evaporative dry eye disease resulting from meibomian gland dysfunction (MGD).
Sight Sciences identifies TearCare as the first and only MGD treatment with this specific functional improvement indication.

Practice Implications

Clinicians can now more definitively frame TearCare as a functional restorative treatment for meibomian glands during patient consultations. This specific labeling may assist in patient education and help set clearer expectations for the long-term management of evaporative dry eye symptoms.

Who's Affected

OptometristsOphthalmologistsDry Eye SpecialistsPractice Owners

What's Next

Following this regulatory milestone, Sight Sciences is expected to integrate the functional improvement claims into its marketing and clinical education. Practitioners should monitor for any subsequent shifts in insurance reimbursement or updated clinical guidelines that may result from this more specific indication.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.